EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies.

Authors:
Wang B; Liu Y; Liao Z; Wu H; Zhang B and 1 more

Journal:
Exp Hematol Oncol

Publication Year: 2023

DOI:
10.1186/s40164-023-00405-2

PMCID:
PMC10236851

PMID:
37268997

Journal Information

Full Title: Exp Hematol Oncol

Abbreviation: Exp Hematol Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsAll authors declare they have no conflict interests. Competing interests All authors declare they have no conflict interests."

Evidence found in paper:

"Funding This study was funded by Shanxi Province “136” Revitalization Medical Project Construction Funds, The National Natural Science Foundation of China (82073090 to Lei Zhang)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025